Dry powder and liquid formulations

Optimized dry powder and liquid formulations for GLP-1 receptor agonists like semaglutide address the limitations of current dosage forms by providing stable, effective, and convenient nasal or inhalation delivery, improving bioavailability and compliance.

WO2026078395A1 Publication Date: 2026-04-16NANOPHARM LIMITED
2 Cites 0 Cited by

Patent Information

Application Number
PCT/GB2025/052230
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-10-10
Filing Date
2025-10-10
Publication Date
2026-04-16

AI Technical Summary

Technical Problem

Current oral and injectable GLP-1 receptor agonist dosage forms, such as semaglutide, suffer from poor bioavailability, high cost, and severe side effects, making patient access and compliance challenging, while existing nasal and inhalation delivery methods lack suitable platforms with stable and effective formulations.

Method used

Development of dry powder and liquid formulations comprising GLP-1 receptor agonists, specifically semaglutide, optimized for nasal delivery or inhalation, using excipients like polymeric viscosity modifiers, bulking agents, and permeability enhancers to ensure stability, appropriate particle size, and ease of administration.

Benefits of technology

The formulations provide improved bioavailability, reduce side effects, and enhance patient compliance by offering a stable and convenient delivery route for GLP-1 receptor agonists, expanding the patient population that can benefit from these medications.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Dry powder formulations of GLP-1 receptor agonists, such as semaglutide, dosage forms containing the same, and liquid feedstocks for preparing dosage forms, such as dry powers, that contain GLP-1 receptor agonists, are disclosed. Also disclosed are liquid formulations of GLP-1 receptor agonists, such as semaglutide.
Need to check novelty before this filing date? Find Prior Art